

Dear Customer,

Thank you for downloading RESPeRATE “Clinical Information Brochure” and kudos for taking an active step toward lowering your blood pressure naturally.

RESPeRATE lowers blood pressure by relaxing constricted blood vessels which cause high blood pressure. RESPeRATE does so by harnessing the therapeutic power of slow-paced breathing with prolonged exhalation in a way that is virtually impossible to achieve on your own.

RESPeRATE is so effective, easy, and safe to use, that the US Food & Drug Administration (FDA) cleared it for purchase without a prescription. Nevertheless, we encourage you to print and share the attached “Clinical Information Brochure” with your doctor, as he/she is the person responsible for your overall treatment program.

Since RESPeRATE is not a drug, this information may be your doctor’s first exposure to RESPeRATE here are some points for your discussion:

- It’s the world’s only FDA-cleared non-drug hypertension treatment device
- It’s clinically validated to deliver a significant and sustained reduction in blood pressure.
- It’s not a drug and can be safely used in conjunction with medications
- There are over 250,000 satisfied customers using RESPeRATE
- The only “side effect” reported so far was sleeping better

To ensure you’ll **get results that will make your doctor smile**, when you purchase REPSerate you’ll also receive our LowerPressure™ 60-day text/email support program for NO extra charge. All you are asked to do is RESPeRATE for 15 minutes a day, and see that high blood pressure goes down.

We are so confident that you’ll love RESPeRATE so much that if within 60-days from the delivery date you are not satisfied with your results (or for any other reason) we will refund your full purchase price. This no-risk-offer is for purchases made at www.resperate.com or by calling us directly toll-free 1-800-220-1925. Applicable for purchase made from Resperate Inc. .

Sincerely,

RESPeRATE cares team

Resperate Inc.

www.resperate.com

Phone: (800) 220-1925 **Fax :** (347) 244-7179 **Email:** support@resperate.com

CLINICAL INFORMATION



RESPeRATE HIGHLIGHTS


RESPeRATE, is the world's only FDA-cleared, non-drug, non-invasive hypertension treatment device. It offers all-day sustained BP reduction in 3-4 weeks of use and after close to one million "user's years" its only reported "side effect" is better sleep. Below is a direct quote from the American Heart Association Scientific Statement "Beyond Medications and Diet: Alternative Approaches to Lowering Blood Pressure" [1]

"The overall evidence from clinical trials and meta-analysis suggests that Device-guided slow breathing [RESPeRATE] can significantly lower blood pressure. There are no known contraindications to the use of the device and no adverse effect have been noted"

American Health Association Scientific Statement, Brook RC et al. Hypertension 2013;61(6):1360-1383

PROVEN EFFICACY

Results: 16 Studies



Significant and sustained reduction in blood pressure (BP) within 8 weeks demonstrated when measured at the office [2-18], at home [3-7, 9, 12-13, 17] and with 24-hour ABPM [4, 10, 19].

110/5 mmHg (weighted average) sustained office BP reduction in adults both with controlled and uncontrolled BP (weighted average from the 16 studies performed in adults [2-18]. Patient population ranged from controlled to refractory hypertensives [5], and included comorbidities such as diabetes [9, 11, 17, 19,] and obstructive sleep apnea [14]. Studies performed in the US, Europe, Middle East and Far East.

CLINICAL INFORMATION


PROVEN EFFICACY CONTINUED

Data available from 10 studies [2-8,10-11] show greater BP reductions for:


- Older patients: 16/7 mmHg for >age 65
- Higher initial BP: 17/7 mmHg for systolic BP>160 mmHg
- More time spent in slow breathing (<10 breaths/min).

BP reductions were independent of gender and medications


Age Dependence [8]




Baseline Dependence [8]



Home SBP Reduction within 8 Weeks [7]




Dose-Response Relationship: SBP Reduction Increases with Slow Breathing Time [6]




HOW RESPeRATE WORKS

How




RESPeRATE's patented Respiratory Modulation Therapy taps the body's natural tendency to follow musical rhythms. RESPeRATE analyzes the breathing pattern and composes, in real time, a personalized melody with two distinct inhale and exhale guiding tones. By gradually prolonging the exhalation tone RESPeRATE leads the patient to the therapeutic zone of less than 10 breaths per minute with prolonged exhalation guiding tones.

After each session of device guided breathing, respiration returns to normal, but the beneficial impact on blood pressure accumulates and is maintained with routine use.



Why



RESPeRATE BP lowering effect is rationalized by an acute reduction of the sympathetic neural activity [18, 20, 21] resulting in small blood vessel dilation and a sustained decrease in peripheral resistance and arterial stiffness [15, 22].

HEALTHCARE PROVIDER FAQs

Can the breathing exercises be performed alone, without the device?

Practicing the type of structured, effortless breathing exercises that is needed to reduce blood pressure is very difficult without a personalized coaching device such as RESPeRATE.

What is the recommended course of treatment for RESPeRATE?

RESPeRATE delivers significant blood pressure reductions if used for 15 minutes at least three to four times per week, in order to attain 40 or more minutes of slow breathing (<10 breaths per minute). Additional use is associated with further blood pressure reductions. It is recommended to use RESPeRATE daily.

How long does it take to realize a BP reduction?

In clinical trials, most patients saw a clinically significant reduction in blood pressure after three to four weeks of treatment with RESPeRATE. More reductions occur with consistent use.

How long do the effects of using RESPeRATE last?

Clinical studies show that RESPeRATE provides a sustained, all-day reduction in blood pressure with regular use. Compliance is good because RESPeRATE is relaxing and easy to use.

What is the safety profile of RESPeRATE?

The FDA labeling lists no contraindications. There are no known adverse effects from the use of RESPeRATE.

Is RESPeRATE covered by health insurance?

As a medical device RESPeRATE is eligible for reimbursement by Flexible Spending Account (FSA) and Health Saving Account (HSA) plans. RESPeRATE is not yet covered by Medicare but might be covered by your medical insurance plan.

How can patients attain a RESPeRATE device?

RESPeRATE can be purchased directly at www.resperate.com or by calling 1-800-220-1925. It can also be made available on practitioners' online stores via wholesalers - for more information contact Scientific Affairs at support@resperate.com

REFERENCES

- [1] Brook RC et al. Hypertension. 2013;61(6):1360-1383.
- [2] Schein MH et al, J Human Hyperten 2001; 15(4): 71-278.
- [3] Grossman E et al, J Human Hyperten 2001; 15(4): 263 -269.
- [4] Rosenthal T et al, Am J Hyperten 2001; 14(1): 74 -76.
- [5] Viskoper R et al, Am J Hyperten 2003; 16:484-487.
- [6] Elliott WJ et al, J Clin Hyperten 2004; 6(10) 553-559.
- [7] Meles E et al, Am J Hyperten 2004; 17:370-74.
- [8] Bae JH et al, Korean Hypertension J, 2006; 1:19-23.
- [9] Logtenberg SJ et al. J Hypertens 2007;25:241-6.
- [10] Aydin L et al, J Hyperten 2008; 26 (suppl 2): S371-S372.
- [11] Schein MH et al, J Human Hyperten 2009; 23(5), 325-331.
- [12] Altema MR et al. Blood Press 2009;18:273-279.
- [13] Anderson DE et al. J Hum Hypertens 2010;24:807-813.
- [14] Bertisch SM et al. Appl Psychophysiol Biofeedback 2011;36:173-179.
- [15] Kim JH et al. J Korean Soc Hypertens 2013;19:55-62.
- [17] Landman GW et al. JAMA Intern Med 2013;173:1346-1350.
- [18] Hering D et al. J Hypertens. 2013;31:739-746.
- [19] Howorka K et al. Auton Neurosci 2013;179:131-137.
- [20] Oneda B et al. Hypertens Res 2010;33:708-712.
- [21] Harada D et al. 2014;307:H1159-H1168.
- [22] Parati G et al, In Hypertension Primer Eds. Izzo et al. Lippincott Williams & Wilkins. 3rd Edition 2003, pp. 117-120.